Interv Akut Kardiol. 2012;11(1):6-8

Personalizovaná medicína a její (moľné) postavení v kardiologii

Vladimír Palička
Ústav klinické biochemie a diagnostiky, LF UK a FN Hradec Králové

Published: January 28, 2012  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Palička V. Personalizovaná medicína a její (moľné) postavení v kardiologii. Interv Akut Kardiol. 2012;11(1):6-8.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Adachi T, Nakanishi M, Otsuka Y, Nishimura K, Hirokawa G, Goto Y, Nonogi H, Iwai N. Plasma MicroRNA asa Biomarker of Acute Myocardial Infarction. Clin.Chem. 2010; 56/7: 1183-1185. Go to original source... Go to PubMed...
    2. Anderson JL, Horne BD, Camp NJ, Muhlestein JB, Hopkins PN, Cannon-Albright LA, Mowers ChP, Park JJ, Clarke JL, Nicholas ZP, McKinney JT, Carlquist JF. Joint effects of common genetic variants from multiple genes and pathways on the risk of premature coronary artery disease. Amer.Heart J. 2010; 160/2: 250-256. Go to original source... Go to PubMed...
    3. Brugst JJ, Boersma E, Simoons ML. Tailored therapy of ACE inhibitors in stable coronary artery disease: pharmacogenetic profiling of treatment benefit. Pharmacogenomics 2010; 11/8: 1115-1126. Go to original source... Go to PubMed...
    4. Corsten MF, Dennert R, Jochems S, Kuznetsova T, Devaux Y, Hofstra L, Wagner DR, Staessen JA, Heymans S, Schroen B. Circulating MicroRNA-208b and MicroRNA-499 Reflect Myocardial Damage in Cardiovascular Disease. Circ.Cardiovasc.Genet. 2010; 3/6: 499-506. Go to original source... Go to PubMed...
    5. de Denus S. Pharmacogenomic testing for angiotensinconverting enzyme inhibitors: getting ready for prime time. Pharmacogenomics 2010; 11/10: 1345-1348. Go to original source... Go to PubMed...
    6. Fiotti N, Xiong W, Giansante C. MMP-2 genetic variant and plaque features of instability. Atherosclerosis 2010; 210/1: 43-44. Go to original source... Go to PubMed...
    7. Gasparyan AY, Watson T, Lip GYH. The Role of Aspirin in Cardiovascular Prevention. J.Amer.Coll.Cardiol. 2008; 51/19: 1829-1843. Go to original source... Go to PubMed...
    8. Hubacek JA, Staněk V, Gebauerová M, Pipilčincová A, Dlouhá D, Poledne R, Aschermann M, Skalická H, Matouąková J, Kruger A, Pěnička M, Hrabáková H, Veselka J, Hájek P, Lánská V, Adámková V, Pi»ha J. A FTO variant and risk of acute coronary syndrome. Clin. Chim. Acta 2010; 411/15-16: 1069-1072. Go to original source... Go to PubMed...
    9. Chmelařová M, Palička V. Hypermetylace DNA u ovariálního karcinomu. Klin. Biochem. Metab. 2010; 18/4: 214-218.
    10. Koch W, de Waha A, Hoppmann P, Schömig A, Kastrati A. Haplotypes ans 5A/6A polymorphism of the matrix metalloproteinase-3 gene in coronary disease: Case-control study and meta-analysis. Atherosclerosis 2010; 208/1: 171-176. Go to original source... Go to PubMed...
    11. Mega JL, Simon T, Collet J-P, Anderson JL, Antman EM, Bliden K, Cannon ChP, Danchin N, Giusti B, Gurbel P, et al. Reduced-Function of CYP2C19 Genotype and Risk of Adverse Clinical Outcomes Among Patients Treated With Clopidogrel Predominantly for PCI. JAMA 2010; 304/16: 1821-1830. Go to original source... Go to PubMed...
    12. Nejatizadeh A, Kumar R, Stobdan T, Goyal AK, Gupta M, Tyagi S, Jain SK, Pasha MAQ. CYP11B2 gene haplotypes independently and in concurrence with aldosterone and aldosterone to renin ratio increase the risk of hypertension. Clin.Biochem. 2010; 136/1-2: 136-141. Go to original source... Go to PubMed...
    13. Palička V. Personalizovaná medicína - realita, mýtus, fikce? Čas. Lék. Česk. 2010; 149/10: 460-461.
    14. Raake PW, Koch WJ, Most P: Polymorphisms present in G-protein-coupled receptor kinases and their effect on betablocker treatment. Pharmacogenomics 2011, 12/3: 295-297. Go to original source... Go to PubMed...
    15. Steele FR. Personalized medicine: something old, something new. Person. Med. 2009; 6/1: 1-5. Go to original source... Go to PubMed...
    16. Welzig CM, Park H-J, Naggar J, Confalone D, Rhofiry J, Shea J, Karas RH, Estes NAM, Galper JB. Differential Effects of Statins (Pravastatin or Simvastatin) on Ventricular Ectopic Complexes: G ?i2, a Possible Molecular Marker for Ventricular Irritability. Amer. J. Cardiol. 2010; 105/8: 1112-1117. Go to original source... Go to PubMed...
    17. Winkelmann BR, Herrington D. Pharmacogenomics - 10 yeras of progress: a cardiovascular perspective. Pharmacogenomics 2010; 11/5: 613-616. Go to original source... Go to PubMed...

    Return to the content


    Interventional Cardiology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.